Advantages of TRUS-based delineation for high-dose-rate prostate brachytherapy planning

被引:4
|
作者
Lavoie-Gagnon, Heloise [1 ]
Martin, Andre-Guy [1 ,2 ]
Poulin, Eric [1 ]
Archambault, Louis [1 ,2 ]
Pilote, Laurie [3 ]
Foster, William [1 ]
Vigneault, Eric [1 ,2 ]
Carignan, Damien [1 ,2 ]
Lacroix, Frederic [1 ]
机构
[1] Univ Laval, CHU Quebec, Dept RadioOncol, 11 Cote Palais, Laval, PQ, Canada
[2] Univ Laval, CHU Quebec, Ctr Rech, Laval, PQ, Canada
[3] Hotel Dieu Levis, Dept RadioOncol, Levis, PQ, Canada
关键词
brachytherapy; prostate cancer; delineation; registration; ultrasound; high-dose-rate; MAGNETIC-RESONANCE; RADICAL PROSTATECTOMY; PENILE STRUCTURES; VOLUME; CT; MONOTHERAPY; RISK; MRI; UNCERTAINTIES; INTERMEDIATE;
D O I
10.5114/jcb.2022.113544
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To evaluate the variability of prostate contours delineated on computed tomography (CT) and transrectal ultrasound (TRUS). Material and methods: A TRUS-based high-dose-rate (HDR) brachytherapy procedure was introduced in 2016 in our center. The first thirty patients were additionally imaged with CT immediately after the treatment. In 2018, four different radiation oncologists (ROs: 1, 2, 3, 4) contoured the prostate on both modalities. A volume comparison was performed between CT and TRUS imaging. Using prostate gold fiducial makers, a rigid registration between CT and TRUS was done in 20 of the 30 patients studied. Jaccard index (JI) was computed to evaluate the inter-observer volume delineation agreement. Results: The ratio of TRUS/CT volumes was 0.82 (95% CI: 0.79-0.87%). The mean JI was 87% for CT and 92% for TRUS, when comparing all four ROs; CT and TRUS JIs were significantly different (p < 0.001). The mean JI for the pros- tate on CT was significantly more consistent (p < 0.001) when comparing RO1, 2, and 3 together (RO1-2, RO1-3, and RO2-3; mean = 89%) than when comparing RO4 (newest to clinical practice) to others (RO1-4, RO2-4, and RO3-4; mean = 85%). For TRUS planning, the mean JI was not significantly different (p > 0.05) when comparing all ROs. Conclusions: The inter-observer and intra-observer variability were statistically significantly smaller on TRUS compared to CT-based planning, despite varying ROs clinical experiences. The superior soft tissue contrast offered by TRUS obviates the effect of the ROs experience on prostate contour volumes and enables more reproducible prostate delineation.
引用
收藏
页码:1 / 6
页数:6
相关论文
共 50 条
  • [1] Validation of MRI to TRUS registration for high-dose-rate prostate brachytherapy
    Poulin, Eric
    Boudam, Karim
    Pinter, Csaba
    Kadoury, Samuel
    Lasso, Andras
    Fichtinger, Gabor
    Menard, Cynthia
    BRACHYTHERAPY, 2018, 17 (02) : 283 - 290
  • [2] Learning curve of MRI-based planning for high-dose-rate brachytherapy for prostate cancer
    Buus, Simon
    Rylander, Susanne
    Hokland, Steffen
    Sondergaard, Christian Skou
    Pedersen, Erik Morre
    Tanderup, Kari
    Bentzen, Lise
    BRACHYTHERAPY, 2016, 15 (04) : 426 - 434
  • [3] Prostate segmentation accuracy using synthetic MRI for high-dose-rate prostate brachytherapy treatment planning
    Kang, Hyejoo
    Podgorsak, Alexander R.
    Venkatesulu, Bhanu Prasad
    Saripalli, Anjali L.
    Chou, Brian
    Solanki, Abhishek A.
    Harkenrider, Matthew
    Shea, Steven
    Roeske, John C.
    Abuhamad, Mohammed
    PHYSICS IN MEDICINE AND BIOLOGY, 2023, 68 (15)
  • [4] High dose rate prostate brachytherapy
    Nickers, P.
    Blanchard, P.
    Hannoun-Levi, J-M
    Bossi, A.
    Chapet, O.
    Guerif, S.
    CANCER RADIOTHERAPIE, 2013, 17 (02): : 118 - 124
  • [5] Complications and side effects of high-dose-rate prostate brachytherapy
    Martell, Kevin
    Kollmeier, Marisa A.
    BRACHYTHERAPY, 2021, 20 (05) : 966 - 975
  • [6] Low-dose-rate or high-dose-rate brachytherapy in treatment of prostate cancer - between options
    Skowronek, Janusz
    JOURNAL OF CONTEMPORARY BRACHYTHERAPY, 2013, 5 (01) : 33 - 41
  • [7] Treatment patterns of high-dose-rate and low-dose-rate brachytherapy as monotherapy for prostate cancer
    Barnes, Justin
    Kennedy, William R.
    Fischer-Valuck, Benjamin W.
    Baumann, Brian C.
    Michalski, Jeff M.
    Gay, Hiram A.
    JOURNAL OF CONTEMPORARY BRACHYTHERAPY, 2019, 11 (04) : 320 - 328
  • [8] High-dose-rate brachytherapy boost for prostate cancer: Outcomes and genitourinary toxicity
    Bece, Andrej
    Patanjali, Nitya
    Jackson, Michael
    Whitaker, May
    Hruby, George
    BRACHYTHERAPY, 2015, 14 (05) : 670 - 676
  • [9] A sector-based dosimetric analysis of dose heterogeneity in high-dose-rate prostate brachytherapy
    Mesko, Shane
    Park, Sang-June
    Kishan, Amar U.
    Demanes, D. Jeffrey
    Kamrava, Mitchell
    BRACHYTHERAPY, 2015, 14 (02) : 173 - 178
  • [10] Monotherapeutic high-dose-rate brachytherapy for prostate cancer: A dose reduction trial
    Yoshioka, Yasuo
    Konishi, Koji
    Suzuki, Osamu
    Nakai, Yasutomo
    Isohashi, Fumiaki
    Seo, Yuji
    Otani, Yuki
    Koizumi, Masahiko
    Yoshida, Ken
    Yamazaki, Hideya
    Nonomura, Norio
    Ogawa, Kazuhiko
    RADIOTHERAPY AND ONCOLOGY, 2014, 110 (01) : 114 - 119